Companies Takeda Pharmaceutical Co Ltd FollowTOKYO, July 27 (Reuters) - Japan's Takeda Pharmaceutical (4502.T) posted first-quarter profit that beat analysts' estimates, citing solid sales of mainstay drugs and the launch of new products including its dengue fever vaccine.
Operating profit rose 12% from a year earlier to 168.6 billion yen ($1.2 billion) in the three months through June 30, the drugmaker said.
That compared with an average forecast of 150.7 billion yen from six analysts polled by Refinitiv.
The company held its forecast for full-year operating profit at 349 billion yen.
Analysts expect 481.1 billion yen on average for the year.
Persons:
Takeda, Rocky Swift, Tom Hogue, Robert Birsel
Organizations:
Takeda Pharmaceutical, Refinitiv, Therapeutics, Shire Plc, Nikkei, Thomson
Locations:
Japan, United States, U.S